ArticleRenal failure2025
Aspirin use is associated with attenuated risk of severe acute kidney injury in septic patients: a dual-center retrospective analysis from MIMIC-IV and eICU cohorts.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a systemic inflammatory response syndrome caused by infection, and sepsis-associated acute kidney injury (AKI) markedly increases mortality. Although aspirin's anti-inflammatory properties show therapeutic promise in sepsis, its specific renal protective effects in septic patients remain underexplored. This study investigated the association between aspirin exposure and severe acute kidney injury in septic patients using two databases: MIMIC-IV (73,181 ICU stays, 2008-2022), and eICU (200,859 ICU stays, 2014-2015). Among 45,562 septic patients, cohorts were stratified by aspirin exposure, and outcome variables were compared using multiple statistical adjustment methods including multivariable regression and propensity score analysis. The primary outcome was severe AKI incidence, with secondary outcomes including overall AKI, continuous renal replacement therapy (CRRT), and mortality. Our study suggests that aspirin exposure was associated with significantly lower severe AKI incidence in both databases (adjusted OR 0.35 in MIMIC-IV; 0.84 in eICU), representing risk reductions ranging from 16% to 65%. Secondary outcomes showed that aspirin exposure was associated with reduced kidney injury incidence, mortality rates and continuous renal replacement therapy requirements. These protective associations were consistent with sensitivity analyses and subgroup analyses. Furthermore, these protective effects were observed across different aspirin doses and formulations. However, aspirin may also increase the risk of thrombocytopenia and gastrointestinal bleeding. Our findings suggest that aspirin may be associated with reduced risk of sepsis-related kidney injury and mortality. Nevertheless, prospective randomized controlled trials are needed to confirm these associations, and individualized risk-benefit assessments remain essential before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.